Eric Lefkofsky Takes Another Step for Medicine

The co-founder and CEO of Tempus, Eric Lefkofsky, has recently been featured in the news everywhere because of his bold idea of utilizing the information gathered at his company to combat breast cancer, through a partnership with the University of Chicago and their researchers.

Tempus is a company that develops technological equipment and systems that have taken the frontline of the battle against cancer for themselves. They call it “data-driven cancer treatment,” and is an excellent idea, utilizing real data that is found in hundreds of patients and laboratory animals with the disease, and use this information to gather patterns and possible treatments. They do it utilizing a method that they call “sequencing:” Using genomic and transcriptomic sequencing, the scientists of Tempus can learn more about the health issue and find out more on what causes a significant effect on it.

The CEO, Eric Lefkofsky, was also the co-founder of a company called Lightbank and another one called Groupon, a worldly known e-commerce website that is used across many countries.

The campaign to fight breast cancer with the University is great news for the nation’s medicine advances. With the specialists of the University that have been studying the tumor for years now and the technology provided by Tempus, they will inevitably reach a better understanding of how the disease works and what can impact it.

Eric Lefkofsky announced that his team plans to help make specialized treatments through this process. Why is this important: Not every patient responds to the treatments the same way. Click here to know more.

Tempus has information on over 1,000 patients that were diagnosed with breast cancer before. The length of the data that the company can gather from each patient is so large that it is unlikely that scientists won’t be able to find patterns that they did not know before.

Doctor and Professor OlufunmilayoOlopade, from the University of Chicago, spoke about how breast cancer is a common disease but has little data on patients that had the disease. They could certainly use more information to further the researches against the tumor.

Without specific genetic information about each patient and past patients that had similar conditions, scientists can’t proceed with the treatments with 100% certainty that they will respond to it in a positive way.